In combination with other drugs, immune checkpoint inhibitors may provide a promising treatment option for TNBC patients, particularly those that express high levels of PD‐L1, an increased number of TILs, or have a high tumor mutational burden. This evidence concerns the gene CD274 and neoplasm.